Published in Cancer Res on September 01, 1996
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst (2002) 3.39
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J Biol Chem (2010) 1.79
A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol (2009) 1.74
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis (2000) 1.52
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest (1997) 1.49
Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res (2000) 1.38
Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer (2008) 1.19
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem (2011) 1.10
Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res (2010) 1.04
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov (2012) 1.04
Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer (2005) 1.02
MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis (2003) 1.01
5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin Exp Metastasis (2004) 1.01
Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer (2003) 0.95
Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol (1998) 0.91
Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery (2008) 0.87
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model. Oncotarget (2015) 0.86
Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo. BMC Cancer (2011) 0.85
Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin Exp Metastasis (2000) 0.84
Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. Oncotarget (2015) 0.82
Imaging the impact of chemically inducible proteins on cellular dynamics in vivo. PLoS One (2012) 0.82
The role of the CDH1 promoter hypermethylation in the axillary lymph node metastasis and prognosis. J Breast Cancer (2013) 0.81
LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis. Clin Exp Metastasis (1999) 0.81
Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling. Oncotarget (2016) 0.79
Regulators of Metastasis Modulate the Migratory Response to Cell Contact under Spatial Confinement. Biophys J (2016) 0.79
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clin Exp Metastasis (1999) 0.79
Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies. Clin Exp Metastasis (2004) 0.78
Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival. PLoS One (2012) 0.78
A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to bone. Trans Am Clin Climatol Assoc (2012) 0.76
1α,25-Dihydroxyvitamin D Inhibits the Metastatic Capability of MCF10CA1a and MDA-MB-231 Cells in an In Vitro Model of Breast to Bone Metastasis. Nutr Cancer (2016) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res (2001) 3.43
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Negative regulation of cytokine signaling pathways. Annu Rev Immunol (2000) 2.98
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest (1990) 2.92
Spred is a Sprouty-related suppressor of Ras signalling. Nature (2001) 2.87
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Bacterioplankton: a sink for carbon in a coastal marine plankton community. Science (1986) 2.76
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. Endoscopy (2003) 2.67
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology (1988) 2.60
Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol (1987) 2.59
Germ-line transmission of a planned alteration made in a hypoxanthine phosphoribosyltransferase gene by homologous recombination in embryonic stem cells. Proc Natl Acad Sci U S A (1989) 2.59
Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55
Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun (1997) 2.51
Two cis-acting elements in the 3' untranslated region of alpha-CaMKII regulate its dendritic targeting. Nat Neurosci (2000) 2.34
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
'Small worlds' and the evolution of virulence: infection occurs locally and at a distance. Proc Biol Sci (1999) 2.31
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res (1993) 2.24
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 2.19
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol (1998) 2.17
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol (1999) 2.14
Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med (1974) 2.08
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Management of failed oral fibreoptic intubation with laryngeal mask airway insertion under topical anaesthesia. Can J Anaesth (1993) 2.05
Pathogen invasion and host extinction in lattice structured populations. J Math Biol (1994) 2.05
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Continuous ambulatory radionuclide monitoring of left ventricular function: effect of body position during ergometer exercise. J Nucl Med (1997) 1.99
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
Measles mortality and vaccine efficacy in rural West Africa. Lancet (1983) 1.97
Evolutionarily stable mutation rate in a periodically changing environment. Genetics (1989) 1.96
EUS in cirrhotic patients with and without prior variceal hemorrhage in comparison with noncirrhotic control subjects. Gastrointest Endosc (2000) 1.94
Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol (1986) 1.93
Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A (1993) 1.92
Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res (1989) 1.87
Phospholipids of bacteria with extensive intracytoplasmic membranes. Science (1966) 1.85
Large shifts in pathogen virulence relate to host population structure. Science (2004) 1.84
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med (1987) 1.82
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest (1995) 1.79
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer (2000) 1.78
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
Cancer and bone. Endocr Rev (1998) 1.77
Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis (1994) 1.76
In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature (1981) 1.71
Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. Proc Natl Acad Sci U S A (1986) 1.69
A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood (1998) 1.68
Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res (1986) 1.64
Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat (1994) 1.61
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood (2000) 1.59
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res (2001) 1.57
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun (1989) 1.56
Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology (1991) 1.56
Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (1990) 1.55
Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev (1999) 1.55
Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem (1998) 1.54
The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow. J Clin Invest (1995) 1.53
Alteration of vitamin D metabolism in Mexican-Americans. J Bone Miner Res (1990) 1.53
The evolution of parasite virulence and transmission rate in a spatially structured population. J Theor Biol (2000) 1.53
A murine model of human myeloma bone disease. Bone (1997) 1.53
Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia (1986) 1.52